Tesamorelin 30 mg peptide pen
The GHRH analogue with a completed clinical programme behind it, the class’s evidence benchmark, at thirty milligrams pre-filled.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Discreet dispatch within 24 h
- Research use only
The clinical-grade reference point
Tesamorelin is what this class looks like after full development: GHRH’s active core, protected at the N-terminus against the enzyme that destroys sermorelin in minutes, carried through trials to an approved indication. The trial programme behind that indication is listed on the ClinicalTrials.gov registry. We supply it as research material; the depth of what is known travels with it.
At €325 it is the secretagogue shelf’s premium entry, priced by synthesis and by what the documentation trail is worth. For research anchored to well-characterised compounds, this is the shelf’s strongest claim.
| Compound | Tesamorelin |
| Content | 30 mg, pre-filled |
| Class | Stabilised GHRH analogue |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Completed clinical programme |
| WADA | On the prohibited list |
| Category | Research use only |
Approval belongs to a licensed product in a defined indication, this pen is research material, and the distinction is not small print.
Before the Tesamorelin 30 mg peptide pen reaches the bench
Premium compound, ordinary rules: the fridge does not care what the literature says.
What stands beside it, and why it costs more
Where the pen sits among its shelf-mates, and why the gap is mostly paperwork.
On this shelf the secretagogues act through one hormonal axis and differ on little else. The short GHRPs and the CJC pens beside it prompt the same release for far less money, yet none carries what tesamorelin carries: a history that ran to an approved indication. Its nearest neighbour is sermorelin, the unstabilised take on the same idea, and the gap between them is the distance between a molecule characterised in trials and one still argued over on forums.
That gap is what the premium buys. At the top of the secretagogue shelf, the thirty-milligram pen is priced for a bigger, costlier molecule and for a paper trail the cheaper pens cannot match. Anyone who decides to buy tesamorelin pen stock is paying less for potency than for behaviour that is already mapped. Researchers on a tighter budget, or who need only the pathway and not the record, are better served by the CJC pens beside it.
From anecdote, to a literature
The rare secretagogue whose forum stories and trial record point the same way.
Most compounds here arrive wrapped in anecdote, and a controlled study is mostly subtraction, stripping away what the forums assumed until a measurable effect is left. Tesamorelin inverts that job. Because a completed clinical programme already exists, a researcher starts from characterised behaviour rather than from someone’s logged experience, and the trip from claim to protocol is unusually short. The pen does not make the anecdotes true; it makes them checkable against a literature that, for once, is there.
One thing the forums rarely raise travels with it anyway: tesamorelin sits on the WADA prohibited list, a rule about competitive sport, not a verdict on research material, and our anti-doping page explains which classes that covers. The distinction the noise flattens is between this pen and the licensed product. They are the same molecule under different regimes, approval attaches to a medicine for one named use, while what ships here is research-grade material with a batch certificate. That boundary is what separates a documented experiment from a borrowed headline.
The research-grade alternatives
The same receptor route at research-record depth and friendlier prices.
The science behind Tesamorelin
What separates this compound from everything beside it.
Questions about the Tesamorelin 30 mg peptide pen
For the shelf’s best-documented molecule.